| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
2025 |
|
|
2024 |
|
| |
|
For the Three Months Ended
January 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Net loss: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
(2,018 |
) |
|
$ |
(1,756 |
) |
| CAR-T Therapeutics |
|
|
(1,177 |
) |
|
|
(1,525 |
) |
| Other |
|
|
(18 |
) |
|
|
(9 |
) |
| Total |
|
$ |
(3,213 |
) |
|
$ |
(3,290 |
) |
| Net income (loss) |
|
$ |
(3,213 |
) |
|
$ |
(3,290 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,386 |
|
|
$ |
3,609 |
|
| Less non-cash stock-based compensation |
|
|
(1,055 |
) |
|
|
(1,260 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,331 |
|
|
$ |
2,349 |
|
| Operating costs and expenses excluding non-cash stock-based compensation expense: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
1,467 |
|
|
$ |
1,213 |
|
| CAR-T Therapeutics |
|
|
848 |
|
|
|
1,128 |
|
| Other |
|
|
16 |
|
|
|
8 |
|
| Total |
|
$ |
2,331 |
|
|
$ |
2,349 |
|
| Operating costs and expenses excluding non-cash share based compensation |
|
$ |
2,331 |
|
|
$ |
2,349 |
|
| |
|
January 31,
2025 |
|
|
October 31,
2024 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| Cancer Vaccines |
|
$ |
11,863 |
|
|
$ |
12,917 |
|
| CAR-T Therapeutics |
|
|
6,885 |
|
|
|
8,535 |
|
| Other |
|
|
158 |
|
|
|
139 |
|
| Total |
|
$ |
18,906 |
|
|
$ |
21,591 |
|
| Total assets |
|
$ |
18,906 |
|
|
$ |
21,591 |
|
|